Returning in an in-person capacity on January 25-27, the 6th Tumor Models for Immuno-Oncology Summit 2022 remains dedicated to the preclinical immuno-oncology community - and is the one and only definitive meeting focusing on disease modeling to empower you to:
Validate your preclinical hypothesis, especially on solid tumors' microenvironment and biology.
Increase your model utility and toolbox to recapitulate human physiology and immune response.
Drive your translational and clinical decision with improved pharmacokinetics, efficacy and safety readouts.
Enhance your understanding of candidates' therapeutic index through next gen models.
Share, inspire and meet with your peers and elite model developers to be equipped with the latest technologies and platforms, such as bioinformatics and NGS for a robust predictive biomarker.
We are excited about the return of a face-to-face meeting where we can reconnect with the community. Tailored with industry IO model experts including Amgen, Soteria Therapeutics, GSK, Crown, JAX , this 3-days summit will guide and prepare you for the next gen IO development, increasing your clinical relevancy and speed-to-clinic!
Time: 08:00 to 17:00
Free: USD 0.00
Speakers: Angus Sinclair, Senior Vice President ImmunoOncology, IGM Biosciences, Markus Vallaster, Executive Medical Director - Cell Therapies and Immuno-Oncology, AstraZeneca, Dirk G. Brockstedt, Chief Scientific Officer, RAPT Therapeutics, Erin Simonds, Director, IO Soteria Biotherapeutics, Mark Orr, Senior Principal Scientist, ImmunoOncology and Cellular Therapy, Bristol Myers Squibb, Poonam Yakkundi, Scientist II, IGM Biosciences, Kathryn Michels, Senior Scientist, Umoja Biopharma, Patrick Chow, Scientific Associate Director, Preclinical Imaging, Bristol Myers Squibb, Aldo Pourchet, Co-Founder, CEO/ CSO, Omios Biologics, Thierry Guillaudeux, Senior Vice President, Kineta, Inc, Daniel Corey, Founder, CERo Therapeutics, Sombeet Sahu, Associate Director, Bioinformatics, Nkarta Therapeutics, Inc, Sanjay Khare, SVP, Head Immuno-Oncology, Coherus Biosciencies, Hans Layman, Senior Director, Translational Medicine, Federation Bio, Zhao Chen, Senior Principal Scientist, Novartis Institutes for BioMedical Research (NIBR), Viswanathan Muthusamy, Director, Center for Precision Cancer Modeling and Research Scientist, Yale University, Dean Campbell, Director – Scientific Engagement and Oncology, Crown Bioscience, John Rossi, Senior Vice President, Head of Translational Medicine CERo Therapeutics, Stephanie Casey Parks, Senior Scientist Amgen, Vikash Bhagwandin, Founding Scientist OncoStemyx, Chia-Yung Wu, Senior Principal Scientist Bristol Myers Squibb, Narendiran Rajasekaran, Assistant Professor Northern Carolina University, Yufei Wang, Research Fellow, Department of Cancer Immunology and Virology, Dana-Farber Cancer Institute Harvard Medical School, John P. Murad, Staff Scientist, City of Hope, David Messenheimer, Senior Scientist, Pharmacology, Zymeworks, Kelly Lee Senior, Staff Scientist, Pre-Clinical Lead, Senti Biosciences, Anthony Park, Post Doctoral Researcher, City of Hope, Kimberly Aardalen, Scientific Technical Leader, Novartis Institutes for Biomedical Research (NIBR), Deepali Sawant, Senior Scientist, Amgen, Ismael Samudio, Senior Director Cancer Biology and Translational Science, Notch Therapeutics, Brian Soper, Senior Manager, Technical Information Sciences, The Jackson Laboratory, Brian Soper, Senior Manager, Technical Information Sciences, The Jackson Laboratory, Jonathan Nakashima, CSO, Certis Oncology, Chris Hughes, Founder and CSO, Aracari Biosciences, Jean Viallet, CEO, INOVOTION, Eric Ibsen, President, Studylog Systems, Qingcong Lin, CEO, Biocytogen Boston Corp